Surmodics Statistics
Total Valuation
Surmodics has a market cap or net worth of $535.16 million. The enterprise value is $530.43 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Surmodics has 14.27 million shares outstanding. The number of shares has increased by 0.86% in one year.
| Shares Outstanding | 14.27M |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 4.31% |
| Owned by Institutions (%) | 73.92% |
| Float | 11.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.38 |
| Forward PS | 3.92 |
| PB Ratio | 4.53 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.39 |
| EV / EBITDA | 431.25 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.28.
| Current Ratio | 3.98 |
| Quick Ratio | 3.08 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 11.72 |
| Debt / FCF | n/a |
| Interest Coverage | -2.11 |
Financial Efficiency
Return on equity (ROE) is -1.21% and return on invested capital (ROIC) is -3.14%.
| Return on Equity (ROE) | -1.21% |
| Return on Assets (ROA) | -2.55% |
| Return on Capital (ROIC) | -3.14% |
| Revenue Per Employee | $321,332 |
| Profits Per Employee | -$3,721 |
| Employee Count | 376 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -7.76M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.15% in the last 52 weeks. The beta is 1.20, so Surmodics's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | +31.15% |
| 50-Day Moving Average | 38.87 |
| 200-Day Moving Average | 35.90 |
| Relative Strength Index (RSI) | 31.98 |
| Average Volume (20 Days) | 227,073 |
Short Selling Information
The latest short interest is 317,696, so 2.23% of the outstanding shares have been sold short.
| Short Interest | 317,696 |
| Short Previous Month | 323,570 |
| Short % of Shares Out | 2.23% |
| Short % of Float | 2.81% |
| Short Ratio (days to cover) | 1.35 |
Income Statement
In the last 12 months, Surmodics had revenue of $120.82 million and -$1.40 million in losses. Loss per share was -$0.10.
| Revenue | 120.82M |
| Gross Profit | 97.67M |
| Operating Income | -7.48M |
| Pretax Income | -9.16M |
| Net Income | -1.40M |
| EBITDA | 1.23M |
| EBIT | -7.48M |
| Loss Per Share | -$0.10 |
Full Income StatementBalance Sheet
The company has $38.18 million in cash and $33.45 million in debt, giving a net cash position of $4.72 million or $0.33 per share.
| Cash & Cash Equivalents | 38.18M |
| Total Debt | 33.45M |
| Net Cash | 4.72M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 118.14M |
| Book Value Per Share | 8.28 |
| Working Capital | 60.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.16 million and capital expenditures -$3.70 million, giving a free cash flow of -$5.86 million.
| Operating Cash Flow | -2.16M |
| Capital Expenditures | -3.70M |
| Free Cash Flow | -5.86M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
Gross margin is 80.84%, with operating and profit margins of -6.19% and -1.16%.
| Gross Margin | 80.84% |
| Operating Margin | -6.19% |
| Pretax Margin | -7.58% |
| Profit Margin | -1.16% |
| EBITDA Margin | 1.02% |
| EBIT Margin | -6.19% |
| FCF Margin | -4.85% |
Dividends & Yields
Surmodics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -0.26% |
| FCF Yield | -1.09% |
Analyst Forecast
The average price target for Surmodics is $43.00, which is 14.64% higher than the current price. The consensus rating is "Hold".
| Price Target | $43.00 |
| Price Target Difference | 14.64% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 7, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 7, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Surmodics has an Altman Z-Score of 6.34 and a Piotroski F-Score of 1.
| Altman Z-Score | 6.34 |
| Piotroski F-Score | 1 |